PRESS RELEASE: Study: MDMA-Assisted Psychotherapy Will Be Cost-Effective in the Treatment of PTSD Healthcare value financial savings of MDMA-assisted psychotherapy for PTSD estimated to be better than $103.2 million with a return of 5,553 Quality of Life Years per 1,000 sufferers Santa Cruz, CA, October 14, 2020 –

 

A peer-reviewed examine printed at this time in the analysis journal PLOS ONE demonstrates that MDMA-assisted psychotherapy is remarkably cost-effective when in comparison with at the moment accessible therapies for submit traumatic stress dysfunction (PTSD). It is estimated {that a} public healthcare payer or non-public insurer making MDMA-assisted psychotherapy accessible to 1,000 sufferers with PTSD would scale back basic and psychological well being care prices by $103.2 million over 30 years.

 

Lead creator Elliot Marseille, Dr.P.H., M.P.P., elaborates, “MDMA-assisted psychotherapy is conducted by a licensed psychologist and trained clinician over the course of twelve sessions with three sessions lasting six or more hours.

 

The cost of that time is not inconsiderable, but in just over three years, healthcare providers will break even on the costs of mental health and general medical care. These estimates are promising yet likely too conservative: the study did not measure the value of increased productivity or lower disability payments as patients recover from PTSD and is constrained by the limited availability of data on the long-term trajectory of PTSD.

 

Further research will be needed to determine the full financial, personal, and societal benefits of MDMA-assisted psychotherapy for PTSD.” Berra Yazar-Klosinski, Ph.D., Deputy Director and Head of Research Development and Regulatory Affairs for MAPS Public Benefit Corporation and co-author, developed the protocols learning MDMA-assisted psychotherapy.

 

She notes, “A growing body of evidence suggests that MDMA-assisted psychotherapy may be more effective than currently available treatments for PTSD, a notoriously difficult-to-treat condition. Previous research has focused on safety and efficacy and indicates statistically significant improvements over psychotherapy with a control, demonstrating reduction in symptoms for 82% of participants.

 

This study should compel healthcare providers to include MDMA-assisted psychotherapy as a covered treatment for PTSD following FDA approval.” Rick Doblin, Ph.D., Executive Director of MAPS and a examine co-author, states, “The profound personal toll of PTSD can include deterioration in physical health, relationships, and ability to participate in social activities along with the anxiety, insomnia, and suicidal ideation that mark the condition.

 

By demonstrating a return of an average of 5.5 quality-adjusted life-years over 30 years, we have shown that MDMA-assisted psychotherapy has the potential to reduce more than the personal burden of PTSD, contributing to improved health outcomes and reduced healthcare burdens for payers and providers.” The cost-effectiveness of MDMA-assisted psychotherapy from the U.S. healthcare payers’ perspective was constructed with a decision-analytic Markov mannequin to painting the prices and well being advantages of treating sufferers with continual, extreme, or excessive, treatment-resistant PTSD.

 

Efficacy was primarily based on the pooled outcomes of six randomized managed trials with the 105 topics who participated in Phase 2 trials and a four-year follow-up of 19 of these topics. Other inputs have been primarily based on printed literature and on assumptions when knowledge have been unavailable.

 

Results are modeled over a 30-year analytic horizon and performed intensive sensitivity analyses. The mannequin calculates anticipated medical prices, mortality, quality-adjusted life-years, and incremental cost-effectiveness ratio. NOTE: The security and efficacy of MDMA-assisted psychotherapy is at the moment below investigation. This remedy has not but been accredited by the FDA, doesn’t work for everybody, and carries dangers even in therapeutic settings. To be taught extra, please go to mdmaptsd.org.

Full Publication https://journals.plos.org/plosone/art…

Multidisciplinary Association for Psychedelic Studies (MAPS) https://maps.org

MAPS Public Benefit Corporation (MAPS PBC) https://mapspublicbenefit.com

MAPS-Sponsored Research: MDMA-Assisted Psychotherapy for PTSD https://maps.org/mdma

Participate in Research: MDMA-Assisted Psychotherapy for PTSD https://mdmaptsd.org

Source link